# Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.

> **NCT04625985** · PHASE2 · COMPLETED · sponsor: **Laboratorios Silanes S.A. de C.V.** · enrollment: 20 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2

## Interventions

- **DRUG:** Metformin Glycinate
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04625985
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-14
- **Primary completion:** 2021-03-08
- **Final completion:** 2021-03-18
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625985, "Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04625985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*